stockportfolio.pro
Stocks / HROW vs URGN
HROW vs URGN
Harrow, Inc. and UroGen Pharma Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Harrow, Inc. (HROW) | UroGen Pharma Ltd. (URGN) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $272.30M | $109.79M |
| Net income (latest FY) | $-5.14M | $-153.49M |
| Revenue growth (5y CAGR) | 41.0% | 56.2% |
| Net margin | -1.9% | -139.8% |
| Return on equity | -9.8% | 145.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HROW — free Open URGN — freeFrequently asked questions
Which is bigger, HROW or URGN?
UroGen Pharma Ltd. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, HROW or URGN?
Over the last five fiscal years, UroGen Pharma Ltd. grew revenue faster — 56.2%/yr versus 41.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.